Diagnostic Delay of Psoriatic Arthritis of More Than Six Months Contributes to Poor Patient-Reported Outcome Measures in Depression, Social Ability, and Disease Impact: A Cross-sectional Study.
Our results demonstrate that delays between PsA symptom onset and diagnosis that are greater than six months lead to increased likelihoods of depression, social disengagement, and impaired quality of life, and that longer delays lead to increasingly worse outcomes in these domains.
Authors
- Gretchen D Ball
- M. Elaine Husni (ORCID: https://orcid.org/0000-0002-3181-4205)
- Neel Tapryal
- Lourdes M. Pérez-Chada (ORCID: https://orcid.org/0000-0001-7724-7309)
- Joseph Frank Merola (ORCID: https://orcid.org/0000-0001-6514-4353)
- Alice Bendix Gottlieb (ORCID: https://orcid.org/0000-0002-2927-8618)
- George Gondo (ORCID: https://orcid.org/0000-0002-6468-0397)
- Michael J. Woodbury (ORCID: https://orcid.org/0000-0002-5057-557X)
- Melissa P. Zundell (ORCID: https://orcid.org/0000-0002-4900-8041)
Institutions
- Brigham and Women's Hospital (US)
- Cleveland Clinic (US)
- ASIS Foundation (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- PubMed
- Published
- 2024-10-01
- Citations
- 1
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- Amgen
- Bristol-Myers Squibb
- National Psoriasis Foundation
- Eli Lilly and Company
- Biogen
- Regeneron Pharmaceuticals
- XBiotech
- Sun Pharma
- LEO Pharma